Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Varsha Gandhi, PhD, on Ibrutinib

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




May
15
Today In Oncology
Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases
First-Line TFOX vs FOLFOX in Advanced HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma
Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations
NCCN Clinical Practice Guidelines in Oncology: 2025 Updates
FDA OCE Announces Project Interface Outreach Initiative
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo